# Metabolic & Weight Research Peptides: Trials, Approvals and What Comes Next > peptidemedsolutions — Metabolic & Weight Research Peptides — A clinical-literature briefing on Metabolic & Weight Research research peptides: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), tesamorelin (Egrifta) and retatrutide, which has no brand name. What each is, what the trials showed, what to watch, and what is still unknown. No dosing, nothing for sale. **METABOLIC & WEIGHT RESEARCH** Four compounds at four different points on the clinical-programme ladder — one approved across three organ systems, one approved and outperforming it, one still investigational, and one approved for a single narrow indication. This desk reads each off the published record. ### [Semaglutide](/semaglutide) ![Semaglutide research illustration](images/semaglutide.webp) Marketed as Ozempic, Wegovy and Rybelsus. The single-arm reference point — a GLP-1 receptor agonist with the deepest outcome-trial base of the four, with weight, cardiovascular events and kidney events all measured in dedicated randomised trials. ### [Tirzepatide](/tirzepatide) ![Tirzepatide research illustration](images/tirzepatide.webp) Marketed as Mounjaro and Zepbound. The lead compound here, and the first approved dual incretin agonist — GIP and GLP-1 receptors engaged by one 39-amino-acid peptide, and the winner of the only head-to-head trial against semaglutide. ### [Retatrutide](/retatrutide) ![Retatrutide research illustration](images/retatrutide.webp) No brand name, because nothing has been approved to carry one. Three receptor arms at once — GIP, GLP-1 and glucagon — producing the largest phase 2 weight reductions reported in this class, alongside an unsettled long-term safety picture. ### [Tesamorelin](/tesamorelin) ![Tesamorelin research illustration](images/tesamorelin.webp) Marketed as Egrifta. The outlier, and not an incretin drug at all — a growth-hormone-releasing hormone analogue approved for one narrow indication, whose trials measure visceral and liver fat by imaging rather than weight on a scale. ## The short version This is a briefing desk, not a clinic and not a shop. It summarises what the published trial literature reports about four peptides studied for weight and metabolic disease: semaglutide (sold as Ozempic, Wegovy and Rybelsus), tirzepatide (sold as Mounjaro and Zepbound), retatrutide, and tesamorelin (sold as Egrifta). Most people meet these compounds by their brand name first and their drug name second. The brand is the package; the peptide inside is what the research is about, and that is what this desk tracks. Retatrutide has no brand name at all, because no regulator has approved it for sale. Three of the four are *incretin mimetics* — laboratory-made copies of hormones the gut releases after a meal to signal fullness and steady blood sugar. The fourth, tesamorelin, works further upstream, on the pituitary hormone axis that governs how the body stores fat around the internal organs. What actually separates these four is not marketing. It is position in a clinical programme: how many receptors a molecule switches on, how far its trials have run, and what a regulator has approved it to do. One is approved across diabetes, obesity and heart disease. One is approved and beat it head to head. One is still experimental. One is approved for a single condition and nothing else. Every compound page below follows the same order — what it is, how it works, what the trials showed, what to watch for, and what remains unknown. No page recommends a dose. ## What "research peptides" means on this desk Peptides are short chains of amino acids: the same building blocks as proteins, assembled into much smaller molecules. All four compounds here are *peptide drugs* — synthetic sequences engineered from a natural hormone, then chemically modified so the body cannot clear them within minutes. The usual modification is a fatty-acid arm bolted onto the peptide backbone. It binds reversibly to albumin, the most abundant protein in blood, which shelters the molecule from the kidneys and from the enzymes that would otherwise chop it up. That single design trick is why three of these are once-weekly injections rather than something that has to be given several times a day. The phrase *research peptide* covers very different regulatory realities, and this desk keeps them separate: - **Approved prescription medicines.** Tirzepatide, sold as Mounjaro and Zepbound, is an approved dual GIP and GLP-1 receptor agonist, first cleared for type 2 diabetes in May 2022 [6]. Semaglutide, sold as Ozempic, Wegovy and Rybelsus, is approved across type 2 diabetes, chronic weight management, cardiovascular risk reduction in established heart disease, and metabolic liver disease. - **Approved, but for one narrow indication.** Tesamorelin, sold as Egrifta, was approved in the United States in 2010 to reduce excess abdominal fat in people with HIV-associated lipodystrophy [18]. Every other use is off-label. - **Investigational.** Retatrutide has been approved by no regulator and therefore has no brand name — only its generic name and the development code LY3437943. Its entire evidence base is phase 1 and phase 2 data, with phase 3 still running [12]. One point that trips readers up constantly: a single peptide can carry several brand names, because a manufacturer registers a separate brand for each approved indication. Two differently named products can contain exactly the same molecule. The trials below are reported under the drug name throughout, which is how the literature reports them. Those three tiers carry different weights of evidence, and conflating them is the single most common error in writing about this class. ## Where each compound sits in the clinical programme The organising frame here is **metabolic peptides in clinical programmes — trials, approvals and what comes next**. Read in that order, the four form a ladder rather than a shelf. - **[Semaglutide](/semaglutide)** — the single-receptor reference point, and the compound every newer agent is measured against. It carries the largest outcome-trial base of the four: a 68-week randomised trial in 1,961 adults reporting a mean body-weight change of -14.9% versus -2.4% on placebo [4]; a 17,604-participant cardiovascular outcomes trial reporting a hazard ratio of 0.80 (95% CI 0.72–0.90) for major adverse cardiovascular events [3]; and a 3,533-participant trial in type 2 diabetes with chronic kidney disease reporting a hazard ratio of 0.76 (95% CI 0.66–0.88) for major kidney events [2]. - **[Tirzepatide](/tirzepatide)** — the lead on this desk, and the first approved dual agonist [6]. In a 72-week phase 3 trial of 2,539 adults with obesity, the highest study arm reported a mean weight change of -20.9% against -3.1% on placebo [8]. In the only head-to-head trial against semaglutide, 751 adults over 72 weeks, it reported -20.2% versus -13.7% (P<0.001) [1]. - **[Retatrutide](/retatrutide)** — the furthest along the receptor count and the least far along the approval path. Structural work confirms it engages GLP-1, GIP and glucagon receptors with one molecule [13]. A 48-week phase 2 trial in 338 adults with obesity reported a mean body-weight change of -24.2% in the highest study arm against -2.1% on placebo [15]. Nothing about it is approved, and its cardiovascular and kidney outcome trials have not reported. - **[Tesamorelin](/tesamorelin)** — the outlier. It does not touch an incretin receptor. It stimulates the pituitary to release the body's own growth hormone, which drives fat breakdown preferentially in visceral tissue. Its pooled trial data report a mean visceral adipose reduction of -27.71 cm² and a hepatic fat fraction reduction of -4.28% [17], and its 52-week programme reported a sustained -18% visceral fat reduction that reversed on discontinuation [21]. A reader coming to this class from the outside usually wants to know which one is *best*. That is the wrong question in four different ways, and the [comparison page](/compare) sets out why. ## How this desk reads the evidence Three kinds of statement appear across these pages, and they are not interchangeable. Keeping them apart is most of the editorial work here. **Trial data.** Percentages, hazard ratios, participant counts and durations trace to a numbered source on the [references page](/references). Where a figure comes from a study that is not on that list, it is not printed here — the qualitative finding is described instead. There is no unattributed number anywhere on this site. **Regulatory labelling.** Boxed warnings, contraindications and approved indications are statements a regulator has made, not conclusions a trial reached. The thyroid C-cell warning attached to this drug class is the clearest example: it derives from rodent studies at exposures well above therapeutic ones, and a dedicated safety review concluded that the human thyroid- and pancreatic-cancer signals remain ones for which definitive conclusions cannot yet be drawn given how few events there are [5]. The contraindication is real and it is on the label. The confirmed human risk is not the same thing. **Community reports.** Some pages summarise what people using these compounds describe in patient forums and research-use communities. That material is **anecdotal, not clinical evidence** — uncontrolled, unverified, self-selected, and impossible to audit. It appears here because it is often the first honest account of what a side effect actually feels like week to week, and it is always labelled. No dose is ever attached to it. One further note on provenance: most of the highest-quality efficacy evidence for the two approved incretins comes from manufacturer-run phase 3 programmes. That is standard practice for a novel drug rather than a scandal, but it is worth stating plainly when weighing the record. ## What this briefing does not publish Some boundaries are worth naming before a reader goes further, because this is a category where people arrive looking for exactly the thing that is not here. This site publishes **no dosing schedules, no titration plans, no reconstitution or handling procedures, and no sourcing information**. Where a trial dose appears in the text, it is reported as the label of a study arm — the amount participants received under supervision in that specific trial — and never as a suggestion. It sells nothing and links to no vendor. It does not tell anyone what to take, when to take it, or whether to take anything at all. Those decisions require a licensed clinician who can see the patient, review the history, order the labs and take responsibility for the outcome. A literature summary cannot do any of that, and a site pretending otherwise would be doing harm. What is here instead: four careful compound briefings, a [cross-compound comparison](/compare), a [FAQ](/faq) drawn from the questions people actually search, and a single consolidated [references list](/references) covering all four. --- A clinical-literature briefing on metabolic peptides: it reports what the trials measured and names what they left unresolved, and it neither practises medicine nor sells anything.